—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Celltrion Inc (068270.KS) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for 068270.KS, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 57/100 · S&P 500 fund at 71, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-09
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +5.0% over 20 sessions. Factor regime → 2026-10-12
  • Sovereign pressure Index 0.04 · down 0.71 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-09

Company snapshot — Celltrion Inc

068270.KS in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Celltrion develops, manufactures and sells biosimilar medicines that copy already-approved biologic drugs, alongside a small number of original therapies. Its portfolio includes Remsima for rheumatoid arthritis and inflammatory bowel disease, Truxima for lymphoma and leukaemia, and Herzuma for breast and gastric cancer, with further biosimilars in arthritis, cancer, asthma and osteoporosis. It sells across roughly a hundred countries, including the United States and Europe, and is headquartered in Incheon, South Korea.
Where it sits in the stack
Celltrion carries no seat in our index; it sits in the healthcare and biotechnology sleeve of our universe, outside the AI build-out stack the diary otherwise follows.
Who it is priced against
No peer group is recorded for it in the diary; the comparison the market draws is with Samsung Biologics, another Korean biosimilar maker.
Why Closelooknet tracks it
It carries no index seat and no Closelooknet score, and the diary has not yet quoted it in the dailies.
What the diary watches
Whether new biosimilar approvals or expiring patents on the originator drugs it copies change the pace of its sales across its main markets.

Celltrion Inc (068270.KS) trades on the KO exchange in South Korea.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return trailing yield 0.40%, annual · last 714 KRW on 2025-12-29

Dividends and capital return

What 068270.KS pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 714 KRW per share · a 0.40% yield on the 2026-10-12 close 1 distribution, paid once a year 2026-10-12
  • Last distribution 714 KRW per share as the price series records it, within days of the ex-date 2025-12-29
  • By calendar year 2025: 714 KRW (partial) first distribution recorded in the three-year window: 2025-12-29

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-13

Quick answers

What is Celltrion Inc (068270.KS)?

Celltrion Inc trades as 068270.KS on the KO exchange (South Korea) in the Closelooknet research universe, as of the registry build of 2026-10-13.

Is 068270.KS in a Closelooknet index?

Not currently — Celltrion Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-13.

Where does 068270.KS trade against its moving averages?

Mixed moving-average stack: Trades -3.5% vs the 50-day and -4.5% vs the 200-day average, 24.5% below the 52-week high and +13.8% off the 52-week low. Computed from daily closes. As of 2026-10-12 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

What does Celltrion Inc do?

Celltrion develops, manufactures and sells biosimilar medicines that copy already-approved biologic drugs, alongside a small number of original therapies. Its portfolio includes Remsima for rheumatoid arthritis and inflammatory bowel disease, Truxima for lymphoma and leukaemia, and Herzuma for breast and gastric cancer, with further biosimilars in arthritis, cancer, asthma and osteoporosis. It sells across roughly a hundred countries, including the United States and Europe, and is headquartered in Incheon, South Korea. No peer group is recorded for it in the diary; the comparison the market draws is with Samsung Biologics, another Korean biosimilar maker.

Where does Celltrion Inc sit in the AI build-out?

Celltrion carries no seat in our index; it sits in the healthcare and biotechnology sleeve of our universe, outside the AI build-out stack the diary otherwise follows. It carries no index seat and no Closelooknet score, and the diary has not yet quoted it in the dailies.

Does Celltrion Inc pay a dividend?

Celltrion Inc has paid 714 KRW per share over the last twelve months, paid once a year, a trailing yield of 0.40% on the 2026-10-12 close; the last distribution recorded in the price series was 714 KRW on 2025-12-29. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for 068270.KS, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.